Purine derivatives as CD73 inhibitors for the treatment of cancer

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10654884
APP PUB NO 20170044203A1
SERIAL NO

15306197

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Provided are novel purine nucleoside/nucleotide analogues compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are inhibitors of CD73 and are useful in the treatment of cancer.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
BOEHRINGER INGELHEIM INTERNATIONAL GMBHGERMANY INGELHEIM AM RHEIN RHINELAND-PALATINATE

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Cacatian, Salvacion Conshohocken, US 49 482
Claremon, David A Maple Glen, US 167 2136
Jia, Lanqi Horsham, US 42 281
Morales-Ramos, Angel Blue Bell, US 15 101
Singh, Suresh B Kendall Park, US 95 1396
Venkatraman, Shankar Lansdale, US 106 957
Xu, Zhenrong Chalfont, US 57 628
Zheng, Yajun Hockessin, US 73 365

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Nov 19, 2027
11.5 Year Payment $7400.00 $3700.00 $1850.00 Nov 19, 2031
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00